Awad R A, Cordova V H, Dibildox M, Santiago R, Camacho S
Experimental Medicine and Motility Unit, Ministry of Health, Mexico City General Hospital; Mexico D.F.
Acta Gastroenterol Latinoam. 1997;27(4):247-51.
Growing evidence points to irritable bowel syndrome physiologically as a disease of the enteric nervous system characterised by hypermotility. The aim of this study was to investigate the action of pinaverium bromide a calcium channel blocker acting selectively on the gastrointestinal tract on basal and post-prandial recto-anal motility of 40 irritable bowel syndrome patients in a random, double blind and placebo controlled trial.
Pinaverium bromide (50 mg) or placebo was taken orally t.i.d. with food. Myoelectrical and mechanical activities of the rectum and the internal anal sphincter were recorded before treatment for 2 h in the fasting state and for an additional 2 h post-prandial.
Post-prandial rectal spike amplitude and frequency as well as the spontaneous recto-anal inhibitory reflex frequency decreased after pinaverium bromide (P < 0.01) but not after placebo.
These results suggest that the calcium channel blockers acting selectively on the gastrointestinal tract may have a therapeutic role in patients with irritable bowel syndrome.
越来越多的证据表明,肠易激综合征在生理上是一种以肠道神经系统功能亢进为特征的疾病。本研究的目的是在一项随机、双盲、安慰剂对照试验中,研究选择性作用于胃肠道的钙通道阻滞剂匹维溴铵对40例肠易激综合征患者基础和餐后直肠-肛门运动的作用。
匹维溴铵(50毫克)或安慰剂与食物一起口服,每日三次。在空腹状态下治疗前记录直肠和肛门内括约肌的肌电和机械活动2小时,并在餐后额外记录2小时。
匹维溴铵治疗后,餐后直肠尖峰振幅和频率以及自发性直肠-肛门抑制反射频率降低(P < 0.01),而安慰剂治疗后无此现象。
这些结果表明,选择性作用于胃肠道的钙通道阻滞剂可能对肠易激综合征患者具有治疗作用。